Disulfidptosis: Fasting and Metformin Boost Anti-PD-1 in Kidney Cancer

SNIPPET: Disulfidptosis is a newly identified form of cell death triggered when glucose-starved cancer cells with high SLC7A11 accumulate toxic disulfide bonds. Research by Wang et al. (2026) demonstrates that intermittent fasting combined with metformin induces disulfidptosis in PBRM1-mutant clear cell renal cell carcinoma, activating immunogenic cell death that enhances anti-PD-1 checkpoint therapy efficacy in preclinical models.

THE PROTOHUMAN PERSPECTIVE#

This is one of those papers that stops you mid-scroll. Not because fasting or metformin are new — they're not — but because the mechanism connecting them to cancer immunotherapy is entirely novel. Disulfidptosis wasn't even named until 2023, and we're already seeing preclinical evidence that a metabolic intervention (fasting + a cheap diabetes drug) can selectively trigger this death pathway in a specific cancer subtype that currently has no targeted therapy.

For the biohacking and longevity community, the implications cut deeper than oncology alone. The same metabolic levers we pull for healthspan — glucose restriction, AMPK activation, mitochondrial efficiency — may be directly relevant to immune system optimization. This isn't about starving cancer. It's about weaponizing a metabolic vulnerability that only becomes lethal under specific nutrient conditions. The convergence of metabolic intervention and immunotherapy represents a shift I've been watching for years, and this paper gives it a mechanistic spine.

THE SCIENCE#

What Is Disulfidptosis, and Why Should You Care?#

Disulfidptosis is a regulated cell death pathway driven by disulfide stress — distinct from apoptosis, ferroptosis, or necroptosis. It was first characterized in 2023 and occurs specifically in cells with high expression of the cystine transporter SLC7A11. Under glucose deprivation, these cells import excessive cystine but lack the NADPH required to reduce it. The resulting accumulation of disulfide bonds causes catastrophic cytoskeletal collapse — actin filament contraction, vesicle formation, and cell death ^[2].

Here's the critical detail: SLC7A11 is significantly upregulated in PBRM1-mutant clear cell renal cell carcinoma (ccRCC). PBRM1 mutations occur in roughly 40% of ccRCC cases and represent a subtype with limited treatment options. There are currently no drugs specifically targeting this mutation ^[1].

The Clinical Observation That Started It All#

Wang et al. (2026) didn't begin with a hypothesis about fasting. They began with a clinical observation: PBRM1-mutant ccRCC patients who also had type 2 diabetes mellitus showed significantly prolonged overall survival and progression-free survival compared to those without diabetes ^[1]. That's counterintuitive — diabetes typically worsens cancer outcomes. So what was different?

The answer, they suspected, was metformin.

Metformin + Glucose Deprivation = Selective Cancer Cell Death#

In their in vitro models, glucose deprivation combined with metformin induced marked cell death specifically in PBRM1-knockout cells. Wild-type cells were far less affected. Microscopic observation revealed the hallmarks of disulfidptosis: cytoskeletal contraction and vesicle formation — not apoptotic blebbing, not ferroptotic lipid peroxidation ^[1].

The confirmation came from pharmacological rescue experiments. Multiple cell death inhibitors were tested. Only 2-methoxyestradiol (2ME), a known disulfidptosis inhibitor, significantly reversed the cytotoxicity. That's a clean mechanistic result — it rules out competing death pathways and pins the effect squarely on disulfide stress.

The Immunogenic Twist#

This is where the paper gets genuinely interesting. Not all forms of cell death activate the immune system — apoptosis, for instance, is typically immunologically silent. But Wang et al. used RNA-seq analysis and in vitro co-culture experiments to demonstrate that disulfidptosis in ccRCC cells constitutes immunogenic cell death (ICD). The factors released by dying cancer cells potently activated T cell-mediated antitumor activity ^[1].

That's not a small finding. It means the metabolic intervention doesn't just kill cancer cells — it turns them into immune system alarm signals. The dying cells essentially recruit and activate the very T cells that anti-PD-1 therapy is trying to unleash.

Fasting + Metformin + Anti-PD-1: The Triple Combination#

In mouse models, intermittent fasting combined with metformin significantly inhibited tumor growth. But the real payoff came when they added anti-PD-1 therapy to the mix. The triple combination enhanced the therapeutic efficacy of checkpoint blockade beyond what any single or dual intervention achieved ^[1].

Let me push back slightly here: these are mouse models with PBRM1-knockout xenografts. The tumor microenvironment in mice, the fasting protocols, the metformin dosing — none of these translate directly to human clinical practice without significant caveats. I'd want to see at least a Phase I trial before anyone adjusts their treatment protocol based on this.

The Broader Disulfidptosis Landscape#

This paper doesn't exist in isolation. Lin et al. (2026) mapped disulfidptosis susceptibility across approximately 10,000 TCGA tumors, developing a "D-score" that correlates with glucose starvation sensitivity and identifies cancers most vulnerable to this pathway ^[3]. Their work found that disulfidptosis susceptibility positively correlates with cell-cycle programs and negatively with DNA repair activity — suggesting combination strategies with cell-cycle inhibitors or PARP inhibitors could amplify the effect.

Meanwhile, a pan-cancer analysis published in BMC Cancer established that disulfidptosis-related gene signatures predict both prognosis and immunotherapy responsiveness across multiple cancer types ^[4]. The DFRS score they developed reflects immune characteristics of the tumor microenvironment and predicts ICI response — giving this death pathway broader relevance beyond renal cancer.

Separately, work published in Nature Metabolism by a team studying dietary restriction showed that caloric restriction reprograms CD8+ T cell fate in the tumor microenvironment. Their key finding: dietary restriction drives enhanced ketone body oxidation (particularly β-hydroxybutyrate), which fuels T cell oxidative metabolism, increasing mitochondrial membrane potential and TCA cycle-dependent pathways critical for effector function ^[5]. DR synergized with anti-PD1 therapy in melanoma models, with combination-treated mice showing significantly delayed tumor onset (P < 0.0001 for DR vs. ad libitum feeding; P = 0.005 for DR+anti-PD1 vs. DR alone) ^[6].

COMPARISON TABLE#

THE PROTOCOL#

Important caveat: This protocol is based on preclinical data. No human clinical trial has validated this specific combination for ccRCC. If you have cancer, work with your oncologist. This is information, not medical advice.

Step 1. Know your tumor genetics. PBRM1 mutation status and SLC7A11 expression levels are the prerequisites for relevance here. Request next-generation sequencing (NGS) of your tumor if not already performed — most comprehensive genomic profiling panels include PBRM1.

Step 2. Discuss metformin with your oncologist. If you are already on metformin for type 2 diabetes, the Wang et al. data suggests this may confer a survival benefit in PBRM1-mutant ccRCC. Standard dosing ranges from 500 mg to 2,000 mg daily. The preclinical data does not establish an optimal oncologic dose in humans.

Step 3. Consider a structured intermittent fasting protocol. The mouse models used intermittent fasting to achieve glucose deprivation conditions. For humans, a time-restricted eating window (e.g., 18:6 or alternate-day fasting) may approximate this metabolic state. Do not begin fasting during active chemotherapy without oncologist approval — cachexia risk is real and must be monitored.

Step 4. Monitor metabolic markers. Fasting blood glucose, insulin, HOMA-IR, and ketone levels (specifically β-hydroxybutyrate) can help confirm you're achieving the metabolic state that preclinical evidence suggests is relevant. Target fasting glucose below 80 mg/dL and βOHB above 0.5 mmol/L during fasting windows, based on the dietary restriction literature ^[5].

Step 5. If on anti-PD-1 therapy (nivolumab, pembrolizumab), discuss timing of fasting windows relative to infusion cycles. The preclinical data suggests the metabolic intervention primes the immune response — meaning fasting periods may be most beneficial in the days surrounding immunotherapy administration. This is speculative but mechanistically coherent.

Step 6. Track immune response markers. Request periodic assessment of tumor-infiltrating lymphocyte (TIL) composition if biopsy is feasible, or monitor circulating biomarkers including lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), and PD-L1 expression status.

Step 7. Do not self-prescribe 2-methoxyestradiol (2ME). This compound inhibits disulfidptosis — it was used as a control in the study. I mention it because I've already seen it misinterpreted on forums. If the goal is to induce disulfidptosis in tumor cells, 2ME is the opposite of what you want.

What is disulfidptosis and how does it differ from other forms of cell death?#

Disulfidptosis is a form of regulated cell death driven by the accumulation of toxic disulfide bonds in cells with high SLC7A11 expression under glucose-deprived conditions. Unlike apoptosis (programmed, immunologically quiet) or ferroptosis (iron-dependent lipid peroxidation), disulfidptosis involves cytoskeletal collapse through disulfide crosslinking of actin and tubulin proteins. It was first formally described in 2023 and appears to be immunogenic — meaning it activates rather than suppresses immune responses ^[2].

Who might benefit from this combination approach?#

Based on the Wang et al. data, the primary candidates would be patients with PBRM1-mutant clear cell renal cell carcinoma — a subtype representing roughly 40% of ccRCC cases. The observation that PBRM1-mutant patients with concurrent type 2 diabetes (on metformin) showed improved survival is what drove this research. However, I want to be direct: no human trial has tested this combination prospectively. This is hypothesis-generating, not protocol-defining.

How does intermittent fasting contribute to the anti-cancer effect?#

Intermittent fasting creates periods of glucose deprivation that are critical for triggering disulfidptosis in SLC7A11-high cancer cells. Separately, dietary restriction has been shown to reprogram CD8+ T cell metabolism through enhanced ketone body (β-hydroxybutyrate) oxidation, increasing mitochondrial efficiency and reducing T cell exhaustion in the tumor microenvironment ^[5]. These are two complementary mechanisms — one killing cancer cells, the other empowering immune cells.

Why does metformin enhance the effect?#

Metformin inhibits mitochondrial complex I, further compromising cellular energy metabolism and NADPH regeneration. In cancer cells already under glucose stress, metformin amplifies the NADPH deficit that makes disulfide bond reduction impossible — pushing SLC7A11-high cells past the threshold into disulfidptosis. It's essentially tightening the metabolic noose that fasting initiates.

When might clinical trials for this combination begin?#

Honestly, we don't know yet. The Wang et al. paper was published in March 2026, and clinical translation from preclinical mouse data typically takes 2-5 years. The advantage here is that both metformin and intermittent fasting have established safety profiles in humans, which could accelerate the regulatory pathway. Retrospective clinical analyses of PBRM1-mutant ccRCC patients already on metformin could provide early signal data much sooner.

VERDICT#

Score: 7.5/10

The mechanistic logic is clean: PBRM1 mutation → SLC7A11 upregulation → vulnerability to disulfidptosis under glucose deprivation → immunogenic cell death → enhanced anti-PD-1 response. Each link in that chain is supported by experimental data in this paper. The clinical observation (diabetic patients doing better) gives it real-world grounding that most preclinical studies lack.

But it's still preclinical. Mouse models, cell lines, knockout experiments. I've seen too many elegant preclinical stories fail in human trials to score this higher without at least Phase I data. The fact that metformin is generic, cheap, and already widely prescribed gives this a better shot at clinical translation than most — there's no pharma incentive problem blocking it.

The supporting literature on dietary restriction and T cell reprogramming from Nature Metabolism strengthens the biological plausibility considerably. I changed my thinking on fasting-as-immunotherapy after reading that paper — the βOHB mechanism for T cell metabolic reprogramming is compelling and well-controlled.

If you're an oncologist managing PBRM1-mutant ccRCC patients who happen to be on metformin, this paper should be on your radar. If you're a patient, don't redesign your treatment plan around mouse data — but do have the conversation with your care team.